restenosis rates after bare-metal stent implantation are as high as 20%-40% at 6 months [3] . Given this situation the medical community devoted, in the latest years, great efforts to perceive alternative approaches to prevent restenosis [1, 39] . Systemic antiproliferative agents [14] , coronary brachytherapy [11] , contrast medium-antiproliferative formulations [26] have been tested. None has contrasted the central role of drug-eluting stents [16, 19, 40] although their long-term results seemingly limited by the delay in healing related to the risk of late stent thrombosis and hypersensitivity reactions [2, 15, 37] .
Inflammation plays a relevant role among the atherosclerosis and restenosis mechanisms, thus the attempt of reducing inflammatory signalling holds the potential to attenuate restenosis without significantly delaying arterial healing. Recently, although the use of the oral corticosteroid prednisone following bare-metal stent deployment has yielded interesting results [36] a dexamethasone-eluting stent has failed to prove effective [21] . In this setting an angioplasty balloon coated with Genistein, an officially approved and clinically safe flavonoid anti-inflammatory agent not presenting major cardiovascular side effects or common intolerances may represent the most advanced and possibly superior alternative.
The aim of the present study was to test in a porcine model the safety and efficacy of a novel Genistein-eluting [10] balloon preceding coronary stenting. Endothelialization, anti-inflammatory and anti-proliferative effects were appraised at different time points and compared to controls in which the coronary stenting was preceded by conventional angioplasty balloon.
Materials and methods j Study design
Cross-bred young adult female piglets weighting between 35 and 60 kg were investigated conforming to The Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and current practice guidelines. Moreover, the study was approved by the local regulatory committee for animal welfare. Two vessel samples within the left circumflex, the left anterior descending and the right coronary artery were selected from each animal, unless these targets were small (e.g. non-dominant right coronary arteries) or challenging for stenting (e.g. tortuosity or anomalous take-off). The selected coronary arteries were then compared as tests and controls within the same or separate animals. The decision whether to treat the target vessel with a conventional or the Genistein-eluted angioplasty balloon was based on computer-generated random numbers without blocks.
The drug-eluting balloon (Sahajanand Medical Technologies Pvt. Ltd., Gujarat, India) constitutes of a biodegradable polymeric matrix (Poly Lactideco-Glycolide) coated with Genistein (0.7 lg/mm 2 , 112.1 lg on each 3.0 · 17 mm balloon). During the procedures related to the delivery of the coated balloon catheter 15%-20% of the drug is released (within 30-40 s) in the blood stream; the remaining 60%-70% of the drug is intended to reach the local target area (product label data).
In all target vessels the angioplasty was followed by a standard balloon-expandable bare-metal stent implantation. The animals were clinically observed every day until one week postoperatively and then weekly by a board certified veterinarian. In case of any abnormality, a complete veterinary clinical examination and recording was realized. The piglets were sacrificed at one (three treated segments), four (10 treated segments), and within 6 and 8 weeks (12 treated segments) following stent implantation (Fig. 1 ). Coronary segments (1 allocated to conventional and 2 allocated to Genistein-eluted angioplasty balloon) unsuitable for stenting or from piglets dying before the pre-specified time point were excluded.
j Coronary angioplasty and stenting deployment
The animals were given Atropine sulphate, Xylaxine, and Ketamine and subsequent anaesthesia was induced by Thiopentone sodium. Following orotracheal intubation, on ventral recumbence, they were given O 2 -N 2 O (1:1) and Halothane 1.5%-2%. Pancuronium bromide was used as muscle relaxant. The ventral neck area was then clipped, scrubbed with Povidone soap and prepared with Povidone iodine solution based on standard aseptic techniques. Subsequently a 7 French introducer sheath was inserted in the common carotid artery, Amplatz 7 or 6 French left coronary catheters were engaged into the respective coronaries under full heparinisation (3 mg/Kg of body weight). The coronary arteries were imaged by a standard angiographic technique and the target vessel diameters estimated by comparison with the angiographic catheter. The conventional or Genisteineluted angioplasty balloons and the bare-metal stents were delivered using the delivery catheters provided by the respective manufacturer. Balloon inflations were performed at nominal pressure for 40-50 s in both groups. The angioplasty was in all cases followed by a standard balloon expandable bare-metal stent implantation. Over-stretching ratio was limited within 1:1 and 1:3 balloon-diameter ratio, appraised by visual estimation of reference vessel diameter matched with the appropriately sized balloon at nominal dilation pressure. The surgical wound was then closed and dressed as per standard technique. Analgesic and antibiotic coverage was provided for the five following postoperative days. Antiplatelet and anticoagulant therapy was prescribed as listed: clopidogrel hydrochloride 75 mg plus aspirin 75 mg once the day, starting two days before the procedure and maintained up to the end of the study; heparin sodium 3 mg/Kg of body weight IV bolus started during the implantation and not reversed post surgically; two doses of Fraxiparine (0.4 ml each) subcutaneously at 12 h interval post implantation until study end.
j Qualitative and quantitative coronary analysis
The animals were euthanized by an excess dose of intravenous thiopentone sodium following a standard angiographic examination of the target vessels. The gross specimens consisted of the heart with the stents in situ. The heart was perfused with formalin 4% for 20 min and consequently fixed in methyl Carnoy's solution (60% methanol, 30% clorophormium and 10% glacial acetic acid) for 24 h and in pure ethanol for the next 24 h. The entire segment of the blood vessel with the stent was cut at either end from the host vessel and processed. Final inclusion was performed the following morning fixing the specimens pretreated in a clorophormium solution for two hours in formalin melted at 70°C over night. One hundred lm thick sections were cut perpendicular to the long axis of the vessel, at the proximal, mid and distal stent level. The sections were stained with toulidine blue/ haematoxylin and eosin/VVG. In addition, 10 mm thick sections of proximal and distal segments (5 mm from the stent edge) were processed and embedded in paraffin wax and 5 lm thick sections were cut and stained with haematoxylin and eosin. Relevant photomicrographs were taken for each segment of interest.
Histomorphometric variables of the target vessels were analyzed by the NIH Image Program (PC version Scion Image, SCION Corp). Patency was evaluated as the degree of in-stent stenosis by blinded histomorphometry and acute and chronic tissue response by blinded graded histopathology. The evaluated parameters were equivalent luminal diameter, neointimal thickness, percentage of lumen stenosis, total and mononucleocytes cellularity count. Furthermore injury and inflammation scores were appraised as described by Schwartz et al. [27] and Kornowski et al. [9] respectively. Discrepancies were resolved by mutual consensus. 
Results
Overall analysis was conducted on 14 piglets. Twentyfive bare-metal stents were implanted preceded by angioplasty with a conventional balloon in 13 vessels and by the Genistein-eluted balloon in 12 (Fig. 1) . None of the piglets presented clinical abnormalities during the study protocol.
No untoward effects were reported comparing the histomorphometric and histopathologic measures of the vessels treated with Genistein-eluting (n = 2) or conventional angioplasty balloon (n = 1) 1 week after implantation (neointimal thickness 0.03 Vs. 0.03, P = 0.963; percentage of lumen stenosis 6.25 Vs. 5.43, P = 0.550; mononucleocytes cellularity 261.0 Vs. 271.0, P = 0.976; injury score 0 in both groups).
Ten target vessels were explanted at 4 weeks from implantation. Photomicrographs of the specimens at this time point disclosed universal healing and endothelialization in the stent struts (Fig. 2) . The histomorphometric and histopathologic measures comparing the target vessels treated with the Genistein-eluted balloon (n = 4) with those treated with a conventional balloon (n = 6) are reported in Table 1 . Box and whisker plots are visualized in Fig. 3 . The Genistein-eluted balloon group disclosed a significant reduction, at 4 weeks from implantation, of the peristent inflammatory cells count (mononucleocytes 39 ± 32 Vs. 96 ± 29 per square millimetre, P = 0.019; Fig. 4) .
The remaining 12 target vessels were explanted from the piglets within 6 and 8 weeks after the implantation. The histomorphometric and histopathologic measures comparing the vessels treated with Genistein-eluted (n = 6) or conventional angioplasty balloon (n = 6) are reported in Table 2 . Box and whisker plots are visualized in Fig. 5 . The overall trends were towards a reduction of neointimal hyperplasia, of percentage of lumen stenosis, of the injury scores and of the count of inflammatory cells, without reaching nominal statistical significances. 
Discussion
This study provides the first in vivo demonstration of the anti-inflammatory effect of a novel Genisteineluting balloon. In this porcine coronary artery model the tested device provided consistent data on safety and biofunctional efficacy. The coronary arteries of piglets have previously proved to respond in a similar manner to the human coronary arteries after injuries [28, 29] . In fact the in-stent neointimal thickness, usually caused within 28 days from an injury, has been described as identical to the human restenotic neointima. The direct proportional correlation within this neointimal thickening and the degree of the injury has been an extremely relevant finding, permitting the creation of an injury-response regression relationship that quantities the response to the potential therapies [30] . Given this evidence, the porcine coronary models using injuries caused by either stenting or overstretching alone are now accepted standards, by which potential restenosis therapies are studied.
Despite the widespread use of intracoronary stents [9] , in-stent restenosis remains a major clinical problem. In the attempt of achieving the ideal balance between healing and suppression of neointimal hyperplasia previous animal studies [8, 27] have established a significant correlation between the degree of arterial injury caused by the metallic wire coils and the resultant neointimal thickness and lumen stenosis at the stented site. The restenosis and occlusion after initially successful percutaneous pro- Four weeks peri-stent cellularity in a left anterior descending implanted with the conventional angioplasty balloon (focus on total cellularity, a and on mononucleocytes, b) compared to a right coronary artery implanted with the Genistein-eluted balloon (focus on total cellularity, c and on mononucleocytes, d with the arrows indicating mononucleocytes). The sections, 100 lm thick, were stained with toulidine blue/haematoxylin and eosin/VVG cedures seem to be, in a large extent, due to the excessive formation of neointimal tissue in response to the unavoidable injury that occurs during balloon dilation and stent implantation. This process continuing for weeks and months may finally result in the occlusion of the artery lumen. The mechanism driving this process after the initial phase of wound healing is yet not completely clear [17] . In coronary arteries, however, excessive formation of neointima has been successfully inhibited by the implantation of drugeluting stents, providing a platform for sustained drug release, which is believed to be a precondition of successful restenosis inhibition [34] . Their implementation in clinical practice has however disclosed unexpected long-term results due to the delay in healing accompanied by the risk of late stent thrombosis [7, 12] .
Few alternative methods have been tested to distribute specific drugs at the vessel wall sites. An angiographic contrast medium enriched with paclitaxel was found to be associated with an inhibition of neointimal proliferation four weeks after the intervention [25, 33] . Another interesting approach derives from the possibility of coating with antiproliferative drugs the balloons for angioplasty [23, 24, 32] .
On the other hand the inflammation, with subsequent release of chemotactic and growth factors after arterial injury, has been raised as one of the major contributing mechanisms of the restenosis [13, 35] . Despite the paucity of data indicating either causality or correlation between the degree of inflammation after arterial injury and the amount of neointimal formation Kornowski et al. [9] have delineated the role of inflammation in the neointimal formation within stents, with vast potential therapeutic implications. Indeed interventions focused on reducing inflammatory signalling carry the promise of attenuating restenosis without significantly delaying arterial healing. Only recently, the use of the oral corticosteroid prednisone after bare-metal stent deployment has yielded significant reductions in restenosis [20, 36] . Although these interesting results with oral corticosteroids following bare-metal stent deployment a large, multicentre analysis of a dexamethasone-eluting stent in patients with acute coronary syndromes offered a low rate of clinical events at 6 months, but no anti-restenosis effect [21] .
Given these presumptions we aimed to evaluate the effects of an anti-inflammatory drug-eluting balloon. The choice of the coated drug, Genistein, was based on the need of an officially approved and clinically safe agent, not presenting major cardiovascular side effects or common intolerances. Genistein, a phytoestrogen resembling 17b-estradiol, has been typically prescribed in women based on its ability, besides the anti-inflammatory effect, to positively regulate bone cell metabolism without harmful estrogenic activity in the breast and uterus [38] . Furthermore in experimental studies Genistein has proved the ability to inhibit collagen-induced platelet aggregation, enhance NO production from the endothelium, decrease cell apoptosis, and inhibit neointima formation, proliferation and migration of vascular smooth muscular cells [18, 31] . The Genistein-eluting balloon proved safe. No untoward effects were found in any of the animals, including those sacrificed as early as one week post-PCI. An even more relevant finding was the universal healing and endothelialization in the stent struts within 4 weeks.
Even more the tested device proved biological efficacy. The target coronary vessels treated with the Genistein-eluting balloon disclosed, at four weeks, a significant reduction in peri-stent inflammatory cells. This completely quantitative variable is certainly more reliable compared to the inflammatory score, especially in small sample populations as animal studies are. The lack of maintained evident antiinflammatory effectiveness in the animals sacrificed within 6 and 8 weeks does not surprise. As recently standardized, inflammation and healing in pigs coronary arteries suggests a time comparability of approximately 1 to 6 porcine to human, with pigs healing more rapidly [27] . For this reason the inflammatory process may, at this timepoint, be completely resolved. Furthermore the progressive elution of the drug may be close to finalized 6-8 weeks from the implantation.
In the clinical setting, the Genistein-eluting balloon holds the potential to limit inflammation and enhance earlier strut endothelialization following stenting. Further studies exploring the synergy of Genisteineluting balloon followed by drug-eluting stent implantation are thus warranted.
In conclusion, this study is the first in vivo demonstration of the anti-inflammatory effects of a novel Genistein-eluting balloon, providing consistent data on safety and biofunctional efficacy of this device in a porcine coronary artery model. Local delivery of antiinflammatory drugs before implantation of stents might indeed yield significant clinical benefits among patients with coronary artery disease. 
